GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ono Pharmaceutical Co Ltd (OTCPK:OPHLY) » Definitions » Capex-to-Operating-Income

Ono Pharmaceutical Co (Ono Pharmaceutical Co) Capex-to-Operating-Income : 0.03 (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Ono Pharmaceutical Co Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Ono Pharmaceutical Co's Capital Expenditure for the three months ended in Dec. 2023 was $-9.74 Mil. Its Operating Income for the three months ended in Dec. 2023 was $330.53 Mil.

Hence, Ono Pharmaceutical Co's Capex-to-Operating-Income for the three months ended in Dec. 2023 was 0.03.


Ono Pharmaceutical Co Capex-to-Operating-Income Historical Data

The historical data trend for Ono Pharmaceutical Co's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ono Pharmaceutical Co Capex-to-Operating-Income Chart

Ono Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.48 0.29 0.21 0.12 0.10

Ono Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.23 0.19 0.02 0.03

Competitive Comparison of Ono Pharmaceutical Co's Capex-to-Operating-Income

For the Drug Manufacturers - General subindustry, Ono Pharmaceutical Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ono Pharmaceutical Co's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ono Pharmaceutical Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Ono Pharmaceutical Co's Capex-to-Operating-Income falls into.



Ono Pharmaceutical Co Capex-to-Operating-Income Calculation

Ono Pharmaceutical Co's Capex-to-Operating-Income for the fiscal year that ended in Mar. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-108.458) / 1062.086
=0.10

Ono Pharmaceutical Co's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-9.737) / 330.529
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ono Pharmaceutical Co  (OTCPK:OPHLY) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Ono Pharmaceutical Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Ono Pharmaceutical Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Ono Pharmaceutical Co (Ono Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, JPN, 541-8564
Ono Pharmaceutical is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a global business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe.

Ono Pharmaceutical Co (Ono Pharmaceutical Co) Headlines